Concepedia

Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial

Rohit Loomba, Kris V. Kowdley, José R Rodríguez-Medina, N K Kim, Alina Álvarez, Linda Morrow, Brenda I. Jeglinski, Alicia Clawson, Swapan K. Chowdhury, Gerard Bain,

˜The œLancet. Gastroenterology & hepatology · 2025 · 30 citations · 14 references

DOI

Concepts

References

14

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Rohit Loomba, Mark L. Hartman, Eric Lawitz et al. · New England Journal of Medicine · 2024 · 783 citations

, , +17

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Philip N. Newsome, M. Sasso, Jonathan J Deeks et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 760 citations · Full text

, , +17

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Arun J. Sanyal, Edgar D. Charles, Brent A. Neuschwander‐Tetri et al. · The Lancet · 2018 · 532 citations

, , +14

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Rohit Loomba, Arun J. Sanyal, Kris V. Kowdley et al. · New England Journal of Medicine · 2023 · 442 citations · Full text

, , +9

The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue

Andrew C. Adams, Chaofeng Yang, Tamer Coşkun et al. · Molecular Metabolism · 2012 · 258 citations · Full text

, , +17